Whitehurst M M, Aldenderfer P H, Sooy M M, Strelkauskas A J
Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, USA.
Hum Antibodies. 1999;9(3):155-60.
The BT-1 assay which identifies a novel breast tumor associated serum analyte was performed for 143 patients previously diagnosed with breast cancer. Mucin tumor markers CA15-3/CA27-29 values were available for 50 patients and there was very minor overlap between patients positive by both tests. Patients' follow-up clinical status at sample draw was compared to BT-1 assay results. 27% of patients originally diagnosed as Stage II and 20% patients originally diagnosed as Stage III who were evaluated 'no disease' had positive BT-1 values. 8% patients diagnosed as Stage II had negative BT-1 results in samples drawn within 90 days of chemotherapy initiation, whereas 23% of patients diagnosed as Stage III cancer were BT-1 test positive within 90 days of chemotherapy initiation. 50% of patients tested before initial breast cancer surgery had positive BT-1 values, suggesting that the BT-1 assay may be useful in identification women with more advanced disease at diagnosis.
对143例先前诊断为乳腺癌的患者进行了BT-1检测，该检测可识别一种新型的乳腺癌相关血清分析物。50例患者有黏液肿瘤标志物CA15-3/CA27-29的值，两种检测呈阳性的患者之间重叠非常少。将患者采血时的随访临床状态与BT-1检测结果进行比较。最初诊断为II期且评估为“无疾病”的患者中有27%的BT-1值为阳性，最初诊断为III期且评估为“无疾病”的患者中有20%的BT-1值为阳性。诊断为II期的患者中有8%在化疗开始后90天内采集的样本中BT-1结果为阴性，而诊断为III期癌症的患者中有23%在化疗开始后90天内BT-1检测呈阳性。50%在初次乳腺癌手术前接受检测的患者BT-1值为阳性，这表明BT-1检测可能有助于识别诊断时患有更晚期疾病的女性。
